HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Oren Livnat reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $40 price target.
Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) announced topline results from Phase 1b Callisto trial designed to evaluate TP-05, a novel investigative oral therapeutic…
Tarsus To Present Saturn-2 Pivotal Phase 3 Trial Data And Saturn-1 Extension Study Long-term Safety Data Evaluating TP-03 For The Treatment Of Demodex Blepharitis At Upcoming Eye Care Meetings
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows.
31 Stocks Moving In Monday’s Mid-Day Session
Gainers
Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition.
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
HC Wainwright & Co. Initiates Coverage On Tarsus Pharmaceuticals with Buy Rating, Announces Price Target of $40
HC Wainwright & Co. analyst Oren Livnat initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and announces Price Target of $40.